Sef Kurstjens Net Worth

Sef Kurstjens biography

Dr. Sef P. Kurstjens, M.D., Ph.D. is an Independent Director of the Company. From April 2013 to April 2018, Dr. Kurstjens served as Chief Medical Officer at Astellas Pharma Inc. At Astellas, Dr. Kurstjens was responsible for development, regulatory affairs, medical affairs, pharmacovigilance and quality assurance and was a member of the Corporate Executive Committee. From 2010 to 2013, Dr. Kurstjens was the President and Chief Executive Officer at Agensys, Inc., an early stage oncology Astellas affiliate. From 2007 to 2010, Dr. Kurstjens served as the Senior Vice President, Chief Medical Officer and Head, Global Drug Development at Allergan plc. Dr. Kurstjens entered the pharmaceutical industry with Sandoz Pharmaceuticals (now a Novartis International AG company) in Basel, Switzerland in 1991, and from 1993 to 2005 held positions of increasing responsibility with Pfizer Inc. in both Europe and the United States, including Vice President Worldwide Therapeutic Area Head of Gastrointestinal and Genitourinary. Dr. Kurstjens received his qualifications in medicine and physiology from University of the Witwatersrand in Johannesburg, South Africa. Our board of directors believes that Dr. Kurstjens’s experience in various research and development roles for biopharmaceutical companies qualifies him to serve as a member of our board of directors.

What's Sef Kurstjens's mailing address?

Sef's mailing address filed with the SEC is C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVE., SUITE 100, IRVINE, CA, 92617.

Insiders trading at Urovant Sciences Ltd

Over the last 6 years, insiders at Urovant Sciences Ltd have traded over $0 worth of Urovant Sciences Ltd stock and bought 22,782,569 units worth $411,146,115 . The most active insiders traders include Sciences Ltd. Roivant, Global Investors Lp Viking ... и Andrew Lo. On average, Urovant Sciences Ltd executives and independent directors trade stock every 6 days with the average trade being worth of $6,293,420. The most recent stock trade was executed by Chemical Co., Ltd.Sumitomo ... on 19 February 2020, trading 103,250 units of UROV stock currently worth $1,350,510.

What does Urovant Sciences Ltd do?

Urovant Sciences Ltd executives and stock owners

Urovant Sciences Ltd executives and other stock owners filed with the SEC include:

• Cornelia Haag-Molkenteller,
  Chief Medical Officer of USI
• Bryan Smith,
  General Counsel - USI
• Michael McFadden,
  Chief Commercial Officer
• Christine Ocampo,
  Senior Vice President, Chief Accounting Officer, Principal Accounting Officer
• Kenton Stewart,
  Senior Vice President of Market Access
• Walt Johnston,
  Senior Vice President of Commercial
• James Hindman,
  Director
• Shigeyuki Nishinaka,
  Director
• Ajay Bansal,
  Chief Financial Officer, Senior Vice President - Business Development, Principal Financial Officer
• Myrtle Potter,
  Chairman of the Board
• James Robinson,
  Principal Executive Officer, Director
• Pierre Legault,
  Independent Director
• Sef Kurstjens,
  Independent Director
• Holdings Ltd.Dexcel Pharma ...,
  
• Associates Gp Llcqvt Fund V...,
  
• Patrick Machado,
  
• Frank Torti,
  Director
• Global Investors Lp Viking ...,
  
• Investments (Uk) Ltd Soft B...,
  
• Nori Ebersole,
  SVP&CHRO-Urovant Sciences,Inc.
• Global Performance Llc Viki...,
  
• Sciences Ltd. Roivant,
  10% owner
• Andrew Lo,
  
• Global Performance Llc Viki...,
  
• Associates Gp Llcqvt Financ...,
  
• Chemical Co., Ltd.Sumitomo ...,
  
• Keith Katkin,
  PEO;CEO/Urovant Sciences, Inc.